Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia Syndrome -Multi-center, Open-label, historical Control Comparative Study-
	Primary sponsor	Toyama Chemical Co., Ltd.
	Study Type	interventional (drug)
	Summary	To evaluate the efficacy and safety of Favipiravir against Severe Fever with Thrombocytopenia Syndrome
Details of study	Interventional drug name	Favipiravir (T-705)
	Target illness	Severe Fever with Thrombocytopenia Syndrome (SFTS)
	Classification name (code) of the investigational drug	625 Antivirals
	Administration route	Oral Multiple Dose
	Control drug name(code/td)	-
	Classification name (code) of the investigational drug	-
	Administration route	-
	Objectives of the study	To evaluate the efficacy and safety of Favipiravir against SFTS
	Study phase	Phase III
	Study design	Multi-center, open-label, historical control comparative study
	Criteria	Inclusion 1.Age:20 years old to less than 85 years old 2.Sex: No restriction 3.Outpatient/hospitalization: Hospitalization 4.Patients who are strongly suspected of SFTS Exclusion 1.Patients who have shown a trend toward improvement of symptoms. 2.Patients who are using ribavirin or has used ribavirin for this episode of infection 3.Others
	Outcome	efficacy and safety
	Study status	On going
	Duration of the study	-
	Region	Japan
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Data Science and Administration Department
	Contact	Form for Inquiry https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn